EBOS director lifts stake with on-market share purchase

EBOS Group Limited ( (AU:EBO) ) just unveiled an announcement.

EBOS Group director Stuart McLauchlan has increased his personal stake in the company, purchasing 1,500 ordinary shares on market for NZ$36,054.64 on 27 February 2026. The acquisition lifts McLauchlan’s holding from 3,686 to 5,186 shares, signaling a modest vote of confidence in the company from its boardroom and marginally strengthening director-aligned ownership.

While small in absolute terms, the transaction underscores ongoing insider participation in EBOS Group’s equity and may be read by some investors as a positive governance signal. The shares will be registered under JBWere (NZ) Nominees Limited, and the trade was executed in compliance with the company’s securities trading policy, outside any closed trading period.

The most recent analyst rating on (AU:EBO) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a listed company operating in the healthcare and pharmaceutical distribution sector. The group focuses on supplying medicines, medical products and related services across its markets, acting as a key intermediary between manufacturers, healthcare providers and pharmacies.

Average Trading Volume: 140,545

Technical Sentiment Signal: Sell

Current Market Cap: A$4.14B

For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.